Psychiatry
Post-Traumatic Stress Disorder
93
Pipeline Programs↗
33
Active Trials↗
48
Companies Involved↗
Post-Traumatic Stress Disorder is a moderately active landscape with 93 programs across 48 companies. The most active players are Azurity Pharmaceuticals, Pragma, GSK. 40 therapies are approved with 12 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 14
Phase 220
Phase 312
Analysis
Trial Status
150
clinical trials
Completed82 · 55%
Recruiting18 · 12%
Terminated11 · 7%
Withdrawn11 · 7%
Unknown status9 · 6%
Active, not recruiting6 · 4%
Other13 · 9%
Clinical Trials
Trial Activity
150 trials
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
Recruiting·—·Phase 2·NCT05790239·40 enrolled
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
Recruiting·—·Phase 2·NCT05837845·30 enrolled
Silexan in the Treatment Of Posttraumatic Stress Disorder Trial
Recruiting·—·Phase 3·NCT06412757·278 enrolled
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
Recruiting·—·Phase 4·NCT05254405·20 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)